Role of angiotensin II in cardiovascular disease therapeutic implications of more than a century of research

Author(s): Ferrario CM


More than a century of research on the reninangiotensin system (RAS) has uncovered the widespread involvement of angiotensin II (Ang II) in the pathophysiology of cardiovascular diseases. A number of outcomes-based mega trials utilising hard clinical endpoints have revealed beneficial effects of angiotensin receptor antagonists (AIIAs/ARBs) in patients with hypertension, heart failure, diabetic nephropathy, and post-myocardial infarction (MI). The results of these studies not only emphasise the importance of Ang II in the pathophysiology of these diseases but have provided the basis for an evidence-based approach for the use of AIIAs in clinical practice. It is hoped that the next 100 years of research into the RAS will uncover hitherto unimaginable therapeutic opportunities.

Similar Articles

Heart rate and subsequent blood pressure in young adults: the CARDIA study

Author(s): Kim JR, Kiefe CI, Liu K, Williams OD, Jacobs DR Jr, et al.

Diagnosis and treatment of low-renin hypertension

Author(s): Mulatero P, Verhovez A, Morello F, Veglio F

Regional angiotensin II production in essential hypertension and renal artery stenosis

Author(s): Admiraal PJ, Danser AH, Jong MS, Pieterman H, Derkx FH, et al.